jnjinnovation.com
Open in
urlscan Pro
104.18.20.17
Public Scan
Submitted URL: http://www.jjdevcorp.com/
Effective URL: https://jnjinnovation.com/venture-investing-jjdc
Submission: On December 31 via api from US — Scanned from DE
Effective URL: https://jnjinnovation.com/venture-investing-jjdc
Submission: On December 31 via api from US — Scanned from DE
Form analysis 1 forms found in the DOM
<form>
<div class="search-container">
<div class="content-input"><input type="text" placeholder="Enter Text" name="search" class="top-nav jj-light-gray" value=""></div>
<div class="content-box"><button type="submit" class=""></button>
<div class="fadingEffect"></div>
</div>
</div>
</form>Text Content
You need to enable JavaScript to run this app.
Connect with UsSubscribe
* Connect with Us
* Subscribe
* Our Approach
* Focus
* Partner Spotlight
* Our Team
* Innovation Challenges
* News & Events
Venture Investing @ JJDC
DRIVING INNOVATION THROUGH VENTURE INVESTING
* Overview
* Year in Review
* Team
* Partnership
* News
JOHNSON & JOHNSON INNOVATION – JJDC, INC. (JJDC) IS THE STRATEGIC VENTURE
CAPITAL ARM OF THE JOHNSON & JOHNSON FAMILY OF COMPANIES
JJDC finds transformative ideas and helps them mature into potential solutions
for today’s patients.
Guided by a clear, consistent investment strategy aligned with the scientific
goals of Johnson & Johnson, JJDC works hand-in-hand with partners to help
navigate the path to creating breakthrough health innovations.
We invest across sectors—pharmaceuticals, medical devices and consumer
healthcare—and at all stages, from new company creation and seed-level startups
to Series A and beyond, including private investments in public equity (PIPEs).
All of our portfolio companies receive the same unwavering commitment to drive
science and technology towards translation for patient benefit. We take a
long-term approach, deploying the full capabilities of the Johnson & Johnson
Family of Companies, including discovery, clinical development, regulatory
affairs, manufacturing and commercialization.
Our team includes leaders in the healthcare and technology communities, many
with deep R&D experience. This gives us the ability to understand our partners
and provide the help they need.
Every opportunity is unique, with tailored roles and terms that provide the best
path to potential success.
JJDC YEAR IN REVIEW
Learn more about JJDC's recent portfolio activity and strategic investments!
Learn More
MEET THE VENTURE INVESTING @ JJDC TEAM
We are scientists, entrepreneurs, and innovators—here to make your next
breakthrough possible.
All Team Members
<>
slide 4 to 5 of 16
WEI WU
Principal, Venture Investments
ASISH K. XAVIER
Vice President, Venture Investments
ZEEV ZEHAVI
Vice President, Venture Investments
CHRIS PICARIELLO
President, Johnson & Johnson Innovation – JJDC, Inc.
SEAN EVANS
Associate, Venture Investments
V. KADIR KADHIRESAN
Vice President, Venture Investments
CLAIRE LEURENT
Principal, Venture Investments
FIONA MACLAUGHLIN
Principal, Venture Investments
ANURAG MEHTA
Principal, Venture Investments
TAMIR MEIRI
Director, Venture Investments
SANJAY MISTRY
Vice President, Venture Investments New Company Creation - Johnson & Johnson
Innovation, JJDC, Inc.
MARIAN NAKADA
Vice President, Venture Investments
ASHA NAYAK
Vice President, Venture Investments
HIRAK PARIKH
Director, Venture Investments Johnson & Johnson Innovation – JJDC, Inc.
LIOR TEITELBAUM
Principal, Venture Investments
DEBI WATSON
Vice President, Venture Investments
WEI WU
Principal, Venture Investments
ASISH K. XAVIER
Vice President, Venture Investments
ZEEV ZEHAVI
Vice President, Venture Investments
CHRIS PICARIELLO
President, Johnson & Johnson Innovation – JJDC, Inc.
SEAN EVANS
Associate, Venture Investments
V. KADIR KADHIRESAN
Vice President, Venture Investments
BY THE NUMBERS
Year Legacy
New/Follow-on investments in 2021
Onboardings (both acquisition and BD deals with J&J entities) in 2021
Exits (M&A, IPO) in 2021
PARTNER SPOTLIGHT
Accelerating innovation through strategic partnerships
REIMAGINING FIBROBLASTS WITH MESTAG THERAPEUTICS
Mestag Therapeutics, is a company founded in 2020 with the mission to develop
impactful new medicines for patients by targeting discrete fibroblast
sub-populations implicated in disease and to better understand how they
influence immune cells.
Learn More
RELATED NEWS
Hear from industry experts and explore the latest breakthroughs
All News
<>
slide 4 to 5 of 30
Strategic Partners In the News
entrinsic bioscience Secures $49 million in Financing to Accelerate Development
and Commercialization of Next Generation Functional Ingredients and Active
Pharmaceutical Ingredients
June 7, 2021
Strategic Partners In the News
Thirty Madison Raises $140 Million in Series C Financing Led by HealthQuest
Capital
June 3, 2021
Strategic Partners In the News
Quest Diagnostics and Paige Form Collaboration to Advance AI-generated Pathology
Insights to Improve Cancer Diagnosis and Care
May 25, 2021
In the Media
Chris Picariello offers Guest Perspective in Ernst & Young’s Beyond Borders: EY
Biotechnology Report 2022
August 9, 2022
Press Releases
Paige Announces Collaboration to Deploy a Novel AI-Based Biomarker Test for
Advanced Bladder Cancer in Clinical Settings
June 15, 2022
Press Releases
Hangzhou DAC Biotechnology Announces a Collaboration and License Agreement with
Janssen for the Development of Novel Antibody-Drug Conjugates
June 1, 2022
Strategic Partners In the News
Locus Biosciences Announces $35 Million Financing
May 18, 2022
Strategic Partners In the News
Rondo Therapeutics Closes $67 Million Series A Financing to Advance
Next-Generation Immuno-Oncology Platform for Solid Tumors
March 2, 2022
In the Media
Biocom conference charts prospects for life sciences industry amid stock market
volatility
February 25, 2022
In the Media
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1
Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of
Type 1 Diabetes (T1D)
February 2, 2022
Strategic Partners In the News
Navitor Pharmaceuticals Announces Janssen Has Acquired Anakuria Therapeutics,
Inc.
February 2, 2022
Strategic Partners In the News
Iterative Scopes Enters Collaboration to Advance AI and Computer Vision
Technologies for Accelerating IBD Clinical Trials
January 25, 2022
Strategic Partners In the News
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and
New President and CEO, and Updates on Phase 1 Clinical Study in
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
January 20, 2022
Strategic Partners In the News
Iterative Scopes Announces $150 Million Series B to Advance AI-Driven Precision
Medicine for Gastroenterology
January 19, 2022
Strategic Partners In the News
Digital Health Leader Verana Health Secures $150M Series E Funding Round
January 14, 2022
Strategic Partners In the News
AviadoBioTM Raises $80 million in Series A Financing to Advance
Neurodegenerative Gene Therapy Platform
December 2, 2021
In the Media
DePuy Synthes Announces Acquisition of OrthoSpin
December 1, 2021
Strategic Partners In the News
On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine)
injection for Identification of Ovarian Cancer During Surgery
November 29, 2021
Strategic Partners In the News
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First
Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
November 16, 2021
Strategic Partners In the News
Paige Receives First Ever FDA Approval for AI Product in Digital Pathology
September 22, 2021
Strategic Partners In the News
Calypso Biotech Announces First Patient With Celiac Disease Dosed in
anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1b Trial, and
Extension of Series A to €28M
September 9, 2021
Strategic Partners In the News
Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven
Precision Medicine for Gastroenterology
August 4, 2021
Strategic Partners In the News
Mestag Therapeutics Extends Seed Financing To $45 Million And Welcomes New
Investors Forbion, GV (Formerly Google Ventures) And Northpond Ventures
August 3, 2021
Strategic Partners In the News
ImmPACT Bio Announces Completion of Merger with Kalthera to Progress
Next-Generation CAR T Therapies for the Treatment of Cancer
July 23, 2021
Strategic Partners In the News
Ribon Therapeutics Secures $65 Million Financing
July 14, 2021
In the Media
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered
Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy
for Acute Myeloid Leukemia (AML)
July 8, 2021
Strategic Partners In the News
POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics
Company
July 1, 2021
Strategic Partners In the News
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance
Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory
Diseases
June 22, 2021
Strategic Partners In the News
Apollo Therapeutics Completes $145 Million Financing Led by Patient Square
Capital to Expand and Advance Portfolio-Based Drug Development
June 17, 2021
Strategic Partners In the News
Datavant and Ciox Health Announce Merger, Creating the Largest Neutral and
Secure Health Data Ecosystem
June 9, 2021
Strategic Partners In the News
entrinsic bioscience Secures $49 million in Financing to Accelerate Development
and Commercialization of Next Generation Functional Ingredients and Active
Pharmaceutical Ingredients
June 7, 2021
Strategic Partners In the News
Thirty Madison Raises $140 Million in Series C Financing Led by HealthQuest
Capital
June 3, 2021
Strategic Partners In the News
Quest Diagnostics and Paige Form Collaboration to Advance AI-generated Pathology
Insights to Improve Cancer Diagnosis and Care
May 25, 2021
In the Media
Chris Picariello offers Guest Perspective in Ernst & Young’s Beyond Borders: EY
Biotechnology Report 2022
August 9, 2022
Press Releases
Paige Announces Collaboration to Deploy a Novel AI-Based Biomarker Test for
Advanced Bladder Cancer in Clinical Settings
June 15, 2022
Press Releases
Hangzhou DAC Biotechnology Announces a Collaboration and License Agreement with
Janssen for the Development of Novel Antibody-Drug Conjugates
June 1, 2022
STAY CONNECTED!
Looking to learn more about incubation, collaboration or investment
opportunities within the Johnson and Johnson Innovation network? Sign up for our
newsletter to stay in touch!
Subscribe
Visit our parent site Johnson & Johnson
* Approach
* Early Innovation Partnerships
* Venture Investing @ JJDC
* Incubation @ JLABS
* Late Stage Partnerships
* Focus
* Consumer Health
* MedTech
* Pharmaceuticals
* Cross-Sector
ChallengesConnect with UsDiversity, Equity & InclusionSitemapCareersLocations
Sign up to stay in touch with Johnson & Johnson Innovation
Subscribe
JNJInnovationJLABS
Apply JLABS Resident Login
© Johnson & Johnson Innovation, LLC 2022. All Rights Reserved.
Your use of the information on this site is subject to the terms of our Legal
Notice. Please see our Privacy Policy and Do Not Sell My Personal Information
form. This site is published by Johnson & Johnson Innovation LLC which is solely
responsible for its contents. This site is intended for global audiences.
Capitalized product names are trademarks of the Johnson & Johnson Family of
Companies or its affiliates.
WE VALUE YOUR PRIVACY
We want to give you the best experience, so we’d like to use cookies to tell us
how to improve our site, keep things relevant for you and enable social media
functions and ads. For more information (including data sharing with partners)
or to adjust your preferences, see “Cookie Settings”. Click “Accept” if you
agree or “Reject” to use only necessary cookies.
Reject Accept
Cookies Settings
COOKIE PREFERENCE CENTER
When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
Allow All
MANAGE CONSENT PREFERENCES
STRICTLY NECESSARY COOKIES
Always Active
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by
you, which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will then not work.
Cookies Details
FUNCTIONAL COOKIES
Functional Cookies
These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.
Cookies Details
PERFORMANCE COOKIES
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. If you do not
allow these cookies we will not know when you have visited our site, and will
not be able to monitor its performance.
Cookies Details
TARGETING COOKIES
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.
Cookies Details
Confirm My Choices
Back Button
Back
PERFORMANCE COOKIES
Vendor Search Search Icon Filter Icon
Clear Filters
Information storage and access
Apply
Consent Leg.Interest
All Consent Allowed
Select All Vendors
Select All Vendors
All Consent Allowed
* HOST DESCRIPTION
View Cookies
REPLACE-WITH-DYANMIC-HOST-ID
* Name
cookie name
Confirm My Choices